Sernova’s Post

This #InsightsIntoImaging study by Jiangdian Song et al. proposes a pre-therapy PET/CT image-based #DeepLearning approach aimed at improving the #survival benefit and #clinical management of patients with esophageal squamous cell #carcinoma (ESCC). 🔗 https://buff.ly/4cRUN6l

During #CART24, Steve Kalloger, MSc, Head of Research at LC, spoke with Healio | HemOnc Today about the experience of patients who have received CAR-T therapy. This study reveals that the mosaic of side effects experienced by those receiving CAR-T may extend beyond what is typically reported. You can read the rest of the article at: https://lnkd.in/gkkrT5Vz #lymsm

Survodutide (GLP1RA/GCGRA) achieves primary endpoint in Ph2 clinical trial. -- Top-line result: ➡ 83% improvement in biopsy-proven MASH❗ https://lnkd.in/gEGRe5vH

Elexacaftor-tezacaftor-ivacaftor (ETI) in people with cystic fibrosis and no F508del variant A new article describing the impact of expanding ETI label to rare responsive CFTR variants identified based on in vitro models. https://lnkd.in/e9kp55nP

What is the prognostic role of endocardial mapping in Brugada patients? 1. BrS subjects, both with latent and overt type-1 phenotype, exhibited endocardial RVOT areas presenting with marked repolarization dispersion, as highlighted by a longer ARIc values   2. Type-1 phenotype evoked by sodium channel blockade was associated with a marked increase of endocardial repolarization dispersion coherently with a remarkable mean ARIc prolongation https://lnkd.in/djP24g6c Sara Latrofa Valentina Hartwig Lorenzo Bachi Pasquale Notarstefano Silvia Garibaldi Luca Panchetti Paolo Seghetti Umberto Startari Gianluca Mirizzi Maria Sole Morelli Martina Modena Andrea Mazzanti Michele Emdin Alberto Giannoni Andrea Rossi #Epeeps #YEP #Brugadasyndrome

📹BETWEEN THE LINES: Raj Chovatiya, MD, PhD, MSCI; and Christopher Bunick, MD, PhD, analyze clinical trial data, compare treatment efficacies of upadacitinib and dupilumab, evaluate quality of life measures, and emphasize the importance of translating study results into real-world atopic dermatitis management strategies. Discover expert insights on treatment efficacy and real-world application: https://ow.ly/SyWl50TnjMt

In this new episode of #JournalClubSpotlight, we share a study with interesting new data on the usefulness of the new particle-based multi-analyte technology (PMAT) in identifying patients with Systemic Lupus Erythematosus (SLE). The present study aimed to compare the presence of anti-dsDNA, anti-Sm and anti-RiboP autoantibodies measured by CIA and PMAT and, analyze diagnostic and clinical SLE activity performance. 👉 Click here to access the full study https://lnkd.in/dP6JQS9T #Autoimmunity #SpecializedDiagnostics #PoweringPatientCare #Lupus #LaboratoryMedicine #Aptiva #SLE

Many people and organizations fear change or unpredictability – not us. Uncover how we helped launch this FIH #genetherapy study without delays despite regulatory challenges: https://bit.ly/3WTY3t7 #INDApplication #ClinicalResearch #NovelTherapies #NaturalHistoryStudy

💉 Say Goodbye to Frequent Bleeds: Hympavzi is Here! The FDA has approved Hympavzi (marstacimab-hncq)—the first non-factor, once-weekly treatment for Hemophilia A and B in individuals aged 12 and older! Why it matters? Hympavzi uniquely targets a key protein in the blood clotting process, offering a fresh approach to reducing bleeding episodes. Dr. Ann Farrell from the FDA highlights its potential to transform care for those affected by this genetic disorder. Traditionally, hemophilia treatments focus on replacing missing clotting factors, but Hympavzi shifts the paradigm by enhancing the body’s natural clotting abilities. In clinical trials, patients saw their annualized bleeding rates plummet from 38 to just 3.2—an incredible improvement! 💪 While there are some precautions to consider, the promise of Hympavzi to elevate patients' quality of life is truly inspiring. 📊 GlobalData analysis from Patent Analytics tool shows the key players with publications related to “Treating Non-Small Hemophilia A & B “. ⚡ Connect with us today to explore the endless possibilities and propel your business forward!  You can also access our CGT in Hemophilia A and B report here: https://lnkd.in/gMs2DMFT #lifesciences #drugdevelopment #cellandgenetherapy #hemophilia #hematologicaldisorders

For more information on this Oral Abstract where GOG-3059 will be presented during the 2024 ASCO Annual Meeting, go to https://ow.ly/4QV050S0FhW or click in bio. #clinicaltrials #GOGF #GOGPartners #GynecologicOncology #ASCO24